Sep 09, 2021 / 05:25PM GMT
Yigal Dov Nochomovitz - Citigroup Inc., Research Division - Director
Okay. Great. Welcome, everyone, to the afternoon session, Large Molecule Drugs for Oncology -- Framing the Tip of the Spear for Novel Antibodies and Protein Therapeutics. I'm Yigal Nochomovitz, one of the biotech analysts here at Citi. It's my pleasure to have with me the leaders of 5 protein antibody companies, apart from Harpoon Therapeutics, Jerry McMahon, President and CEO; from MacroGenics, Scott Koenig, also President and CEO; from Merus, Bill Lundberg, the CEO; from Shattuck Labs, Taylor Schreiber, the CEO; and from Zymeworks, Ali Tehrani, President and CEO. So welcome, gentlemen, to the program, a lot to discuss today.
But as a starting point, perhaps you could just give a brief introduction to your company. And in doing so, cover what are the strengths and differentiating qualities of your antibody or protein therapeutic platforms. Maybe we could start with Scott.
Scott Koenig - MacroGenics, Inc. - CEO, President & Director
Thank you, Yigal, and it's a real pleasure to
MacroGenics Inc at Citi BioPharma Conference (Virtual) Transcript
Sep 09, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers